Dutasteride

證據等級: L5

預測適應症: 10 個

Dutasteride: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Dutasteride is a dual 5-alpha reductase inhibitor (5-ARI) used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia by suppressing dihydrotestosterone (DHT) synthesis. The TxGNN model predicts it may be effective for Ambras Type Hypertrichosis Universalis Congenita, an ultra-rare genetic disorder characterised by excessive whole-body terminal hair growth. This prediction is at evidence level L5, meaning it rests on model output alone — there are currently no clinical trials and no relevant literature supporting this direction.

Quick Overview

Item	Content
Original Indication	Benign prostatic hyperplasia (BPH); androgenetic alopecia (male pattern hair loss)
Predicted New Indication	Ambras Type Hypertrichosis Universalis Congenita
TxGNN Prediction Score	99.998%
Evidence Level	L5
Canada Market Status	✗ Not marketed (0 DINs on record)
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacology, dutasteride is a potent, irreversible inhibitor of both type 1 and type 2 isoforms of 5-alpha reductase — the enzymes responsible for converting testosterone into the more potent androgen dihydrotestosterone (DHT). By reducing DHT levels in both serum and tissue, dutasteride suppresses androgen-driven processes: prostate epithelial proliferation in BPH, and follicular miniaturisation in androgenetic alopecia. Its dual-isoform blockade distinguishes it from finasteride, which inhibits only type 2.

Ambras syndrome (hypertrichosis universalis congenita, Ambras type) is caused by rearrangements or mutations in the TRPS1 gene at chromosome 8q23–q24, leading to generalised, non-androgen-dependent hypertrichosis. Unlike hirsutism (excess hair driven by elevated androgens) or androgenetic alopecia (hair loss driven by DHT), Ambras syndrome hair growth operates through a completely different biological pathway and is present from birth. Lowering DHT would not be expected to reverse a constitutive defect in TRPS1-mediated hair follicle regulation.

The high TxGNN score (99.998%) most likely reflects the density of shared hair-follicle–related nodes in the underlying knowledge graph rather than a genuine pharmacological relationship. The evidence pack explicitly flags this as a probable KG topological artefact. There is no preclinical model, case report, or mechanistic hypothesis in the published literature linking dutasteride to Ambras syndrome. At this stage, the prediction should be regarded as a false positive generated by network proximity, not biological plausibility.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

No Canadian DIN records are currently available in this dataset for dutasteride. This likely represents a data collection gap rather than true non-availability: dutasteride (brand name Avodart®) is approved and marketed in numerous countries for BPH and androgenetic alopecia. Health Canada’s Drug Product Database should be consulted directly to confirm current DIN status and approved indications before drawing conclusions about market availability.

Safety Considerations

Please refer to the package insert for safety information.

Note: The evidence pack identifies the absence of Health Canada product monograph warnings and contraindications as a blocking data gap (DG001). No drug interaction data was retrieved. A full safety review cannot be completed until the product monograph is obtained and parsed.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite an extremely high TxGNN score (99.998%), the predicted indication — Ambras Type Hypertrichosis Universalis Congenita — is a non-androgenic genetic disorder with no known connection to the DHT/5-alpha reductase pathway. The prediction scores are uniformly high across all 10 ranked indications (all hair-, follicle-, or topology-adjacent conditions), which further supports a systematic KG topology bias rather than specific mechanistic relevance. With zero clinical trials, zero targeted literature, and a missing mechanism of action file, there is no actionable basis for advancing this candidate.

To proceed, the following is needed:

Mechanism of action data: Retrieve the full dutasteride DrugBank entry (DB01126) to formally document MOA and confirm isoform selectivity profile
Health Canada product monograph: Download and parse the Avodart® Canadian monograph to complete the safety review (blocking data gap DG001)
Health Canada DIN verification: Cross-reference against the Health Canada Drug Product Database to correct the apparent 0-DIN data gap
Biological plausibility assessment: Commission a targeted literature review on whether any TRPS1 pathway interactions with androgen signalling have been reported in the basic science literature
KG audit: Investigate why dutasteride achieves >99.9% scores across all hair/follicle-adjacent nodes, including biologically incompatible targets (e.g., Dandy-Walker malformation, diffuse alopecia areata) — this pattern suggests a systematic graph topology artefact that may warrant model recalibration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.